Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

Molecular Therapy

Volumn 26, Issue 7, 2018, Pages 1855-1866

  Kloss, Christopher C ^a,c   Lee, Jihyun ^a,d   Zhang, Aaron ^a   Chen, Fang ^a   Melenhorst, Jan Joseph ^a,b   Lacey, Simon F ^a   Maus, Marcela V ^a,e   Fraietta, Joseph A ^a,b   Zhao, Yangbing ^a   June, Carl H ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Institute for Translational Medicine and Therapeutics   (United States)

^d LG Chemical Ltd   (South Korea)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

chimeric antigen receptor; prostate cancer; TGF

Indexed keywords

LENTIVIRUS VECTOR; MESSENGER RNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; FOLH1 PROTEIN, HUMAN; GLUTAMATE CARBOXYPEPTIDASE II; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THERAPY EFFECT; TUMOR IMMUNITY; CELL LINE; CELL PROLIFERATION; CLINICAL TRIAL; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; T LYMPHOCYTE; TUMOR CELL LINE;

ANTIGENS, SURFACE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PC-3 CELLS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CHIMERIC ANTIGEN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 85047445807     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2018.05.003     Document Type: Article

References (42)

1. Litwin, M.S., Tan, H.J., The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 317 (2017), 2532–2542.
2. Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al., CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15 (2014), 700–712.
3. Chen, D.S., Mellman, I., Elements of cancer immunity and the cancer-immune set point. Nature 541 (2017), 321–330.
4. Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545 (2017), 60–65.
5. Verdegaal, E.M., de Miranda, N.F., Visser, M., Harryvan, T., van Buuren, M.M., Andersen, R.S., Hadrup, S.R., van der Minne, C.E., Schotte, R., Spits, H., et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536 (2016), 91–95.
6. June, C.H., Warshauer, J.T., Bluestone, J.A., Is autoimmunity the Achilles’ heel of cancer immunotherapy?. Nat. Med. 23 (2017), 540–547.
7. Sadelain, M., Rivière, I., Riddell, S., Therapeutic T cell engineering. Nature 545 (2017), 423–431.
8. Lim, W.A., June, C.H., The Principles of Engineering Immune Cells to Treat Cancer. Cell 168 (2017), 724–740.
9. Rabinovich, G.A., Gabrilovich, D., Sotomayor, E.M., Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25 (2007), 267–296.
10. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
11. Chong, E.A., Melenhorst, J.J., Lacey, S.F., Ambrose, D.E., Gonzalez, V., Levine, B.L., June, C.H., Schuster, S.J., PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129 (2017), 1039–1041.
12. Condomines, M., Arnason, J., Benjamin, R., Gunset, G., Plotkin, J., Sadelain, M., Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE, 10, 2015, e0130518.
13. Siegel, P.M., Massagué J., Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3 (2003), 807–821.
14. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
15. Travis, M.A., Sheppard, D., TGF-β activation and function in immunity. Annu. Rev. Immunol. 32 (2014), 51–82.
16. Ebner, R., Chen, R.H., Shum, L., Lawler, S., Zioncheck, T.F., Lee, A., Lopez, A.R., Derynck, R., Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science 260 (1993), 1344–1348.
17. Wieser, R., Attisano, L., Wrana, J.L., Massagué J., Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Mol. Cell. Biol. 13 (1993), 7239–7247.
18. Gorelik, L., Flavell, R.A., Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7 (2001), 1118–1122.
19. Gorelik, L., Flavell, R.A., Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12 (2000), 171–181.
20. Lucas, P.J., Kim, S.J., Melby, S.J., Gress, R.E., Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J. Exp. Med. 191 (2000), 1187–1196.
21. Zhang, Q., Yang, X., Pins, M., Javonovic, B., Kuzel, T., Kim, S.J., Parijs, L.V., Greenberg, N.M., Liu, V., Guo, Y., Lee, C., Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65 (2005), 1761–1769.
22. Donkor, M.K., Sarkar, A., Savage, P.A., Franklin, R.A., Johnson, L.K., Jungbluth, A.A., Allison, J.P., Li, M.O., T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35 (2011), 123–134.
23. Foster, A.E., Dotti, G., Lu, A., Khalil, M., Brenner, M.K., Heslop, H.E., Rooney, C.M., Bollard, C.M., Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother. 31 (2008), 500–505.
24. Bollard, C.M., Tripic, T., Cruz, C.R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C.A., Liu, H., et al. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J. Clin. Oncol. 36 (2018), 1128–1139.
25. 177 Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr. Radiopharm. 9 (2016), 44–53.
26. Bander, N.H., Trabulsi, E.J., Kostakoglu, L., Yao, D., Vallabhajosula, S., Smith-Jones, P., Joyce, M.A., Milowsky, M., Nanus, D.M., Goldsmith, S.J., Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 170 (2003), 1717–1721.
27. Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43 (2015), D447–D452.
28. Beretta, E., Dhillon, H., Kalra, P.S., Kalra, S.P., Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods. Peptides 23 (2002), 975–984.
29. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
30. Ali, S.A., Shi, V., Maric, I., Wang, M., Stroncek, D.F., Rose, J.J., Brudno, J.N., Stetler-Stevenson, M., Feldman, S.A., Hansen, B.G., et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 (2016), 1688–1700.
31. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., Pardoll, D.M., Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254 (1991), 713–716.
32. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H., The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998), 2357–2368.
33. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21 (2015), 581–590.
34. Frigault, M.J., Lee, J., Basil, M.C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O.U., Guedan, S., McGettigan, S.E., Posey, A.D. Jr., et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 3 (2015), 356–367.
35. Lee, J.C., Hayman, E., Pegram, H.J., Santos, E., Heller, G., Sadelain, M., Brentjens, R., In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71 (2011), 2871–2881.
36. Wartewig, T., Kurgyis, Z., Keppler, S., Pechloff, K., Hameister, E., Öllinger, R., Maresch, R., Buch, T., Steiger, K., Winter, C., et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552 (2017), 121–125.
37. Gust, J., Hay, K.A., Hanafi, L.A., Li, D., Myerson, D., Gonzalez-Cuyar, L.F., Yeung, C., Liles, W.C., Wurfel, M., Lopez, J.A., et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 7 (2017), 1404–1419.
38. Fitzgerald, J.C., Weiss, S.L., Maude, S.L., Barrett, D.M., Lacey, S.F., Melenhorst, J.J., Shaw, P., Berg, R.A., June, C.H., Porter, D.L., et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit. Care Med. 45 (2017), e124–e131.
39. Maude, S., Barrett, D.M., Current status of chimeric antigen receptor therapy for haematological malignancies. Br. J. Haematol. 172 (2016), 11–22.
40. Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17 (2009), 1453–1464.
41. Kutner, R.H., Zhang, X.Y., Reiser, J., Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 4 (2009), 495–505.
42. Dupont, W.D., Plummer, W.D. Jr., Power and sample size calculations for studies involving linear regression. Control. Clin. Trials 19 (1998), 589–601.